We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Cell Therapy Close Up

Achieving High Non-Viral Transfection Performance for Cell Therapy Processing

Cell therapies often involve introduction of genetically transformed cells into a patient. Recently there has been renewed interest in non-viral gene modification for this application as an alternative to lentiviral vectors. Non-viral electroporation utilizing CRISPR-Cas9 is continuing to show improved performance and safety benefits in the area of cell-based immunotherapy. Furthermore, because electroporation is easy and rapid, it can transfect a large number of cells in a short time once optimum electroporation conditions are determined.

Watch this webinar to:

  • Understand how process flexibility and ability to optimize electroporation protocols can assist through the process development phase of a cell therapy program
  • Discuss the typical numbers of cells required for cell therapy process development and manufacturing applications
  • Explore the safety, performance and regulatory advantages of mechanical, non-viral transfection for cell therapy

A picture of Nektaria Andronikou
Nektaria Andronikou
Senior R&D Manager
Thermo Fisher Scientific
Brought to you by:

Interested in sponsoring this webinar? Contact our friendly sales team here.
Watch this Webinar for FREE Below
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
Want to invite a colleague?

Click the button below to begin inviting a colleague to this Webinar